TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) – Analysts at William Blair cut their Q1 2022 EPS estimates for Revance Therapeutics in a note issued to investors on Tuesday, March 1st. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings per share of ($0.93) for the quarter, down from their […]